reason report
diversifi alzheim portfolio initi aciu op
pt
bottom line initi aciu op rate
sotp-bas pt thesi three-fold ac immun
diversifi pipelin drug candid diagnost alzheim
diseas ad led late-stag antibodi crenezumab
compani strong partner roch crenezumab
op anti-tau vaccin mp alpha-synuclein-
pet tracer diagnost life molecular imag formerli piram
imag tau-pet tracer diagnost help valid
project fund clinic develop expens program
well commerci product would result solid royalti
stream success ac immun also two proprietari drug
discoveri platform one antibodi small molecul
strong knowledg base neurodegen diseas
enabl compani keep put new product pipelin
catalyst watch includ phase interim data analysi
syndrom preclin lead select data
alpha-synuclein antibodi ad phase cread
data crenezumab ad phase cread data
crenezumab ad
leerink proprietari research underscor conclus
proprietari research report includ follow insight
medacorp physician interview page amyloid
hypothesi crenezumab page tau hypothesi anti-
tau program ad diagnost sotp analys compani
financi model page page respect
pt base sotp analysi forecast cash flow
discount rate risk invest thesi
includ view alzheim diseas trial riski
biopharma therapeut area given numer disappoint
continu question whether amyloid hypothesi valid
crenezumab risk given mix data far roch
ad drug well partner ac immun crenezemab anti-
tau demonstr proof concept yet mani compani
pursu alzheim diseas research ac immun probabl
need rais money continu fund project
link industri report initi
neurosci sector full coverag univers link recent
podcast full initi
sotp analysi forecast cash
flow discount
net debt total capit
year price history/av daili volume mil aciu
creat bluematrix
compani inform leerink partner llc research
revenu million chf ep basic chf
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
ac immun aciu initi outperform pt
tabl content
invest thesi compani snapshot
dual platform misfold protein
crenezumab anti-abeta program
pre-clinical/discoveri program diagnost tool
invest thesi
thesi three-fold
ac immun diversifi pipelin drug candid diagnost alzheim diseas ad led
compani strong partner roch crenezumab op anti-tau vaccin
mp alpha-synuclein-pet tracer diagnost life molecular imag formerli piram imag
tau-pet tracer diagnost help valid project fund clinic develop
expens program well commerci product would result solid royalti stream
ac immun also two proprietari drug discoveri platform one antibodi small
molecul strong knowledg base neurodegen diseas enabl compani keep
put new product pipelin
pt base sum-of-the-part sotp analysi forecast cash flow
view ad trial riski biopharma therapeut area given numer disappoint
continu question whether amyloid hypothesi valid
crenezumab risk given mix data far
roch ad drug
anti-tau demonstr proof concept yet
mani compani pursu ad research
ac immun probabl need rais money continu fund project
ac immun focus develop medicin diagnost tool neurodegen diseas
found
rais
focu develop precis medicin
diagnost tool ad neurodegen
diseas driven protein misfold
compani dual technolog platform
supraantigen biolog morphom sm molecul
crenezumab ad pipelin candid
base amyloid-beta hypothesi
anti-tau antibodi move phase
ad treatment base tau hypothesi
ac immun also develop clinic product
timelin key near-term catalyst
ac immun focus develop medicin diagnost tool neurodegen diseas
phase earlier
ac immun built diversifi portfolio ad program still high-risk/high-reward project
crenezumab major catalyst compani anti-tau product anti-tau antibodi move
proof-of-concept studi provid addit opportun
diagnost tool morphom medicin target abeta tau alpha-synuclein also earli stage studi
compani report leerink estim
compani report chf stock usd
product non-risk adj revenu chf stage developmentnon-risk adj npv chf probabl successrisk-adj npv chf expect launchrisk-adj net current valu share chf risk-adj net current valu share usd pipelinecrenezumab alzheim ad alzheim ad alzheim ad syndrom alzheim ad pet tracer pet tracer royalti adj risk-adj risk-adj risk-adj total asset count fulli dilut rate risk-adjust equiti valu usd exclud unalloc account corpor technolog franchis valu howev valu includ net cash adjust sotp valuat breakdown product indicationcrenezumabadroyaltiesanti-tauad royaltiesdiagnosticsroyaltiesnet adjustmentg aadjustmenttot ac immun sa
asset
po use
ad rti
ad rti
ad rti
down rti
ad rti
diagnost
ad rti
ad rti
ad rti
down rti
ad rti
diagnost
ad rti
ad rti
down rti
ad rti
diagnost
ad rti
ad rti
down rti
ad rti
diagnost
ad rti
ad rti
ad rti
down rti
ad rti
diagnost
ad rti
ad rti
ad rti
down rti
ad rti
diagnost
item shown view sotp valuat
compani report leerink estim
close sotp convert chf compani report po probabl success
rti royalti payment syndrom diagnost includ tau alpha-synuclein pet tracer
ac immun aciu stock volatil due news ad program compani
compani report leerink estim factset data
new formul develop
overview debat
posit phase
data help
valid amyloid
valid tau
anti-tau
advanc
chanc still riski base
higher dosag longer treatment window
posit cognit effect milder ad patient
subgroup phase studi
also high-risk program sinc tau
patholog ad immunotherapi efficaci
need proven tau burden
close relat ad patholog still need
determin proof-of-concept data
gener parallel program
partial de-risk diversifi candid
think keep deliv novel product
clinic develop compani
alreadi demonstr platform
product therapeut program
deep knowledg neurodegener
support studi misfold protein
thesi strong collabor
leverag oper
risk
abeta hypothesi still
proven
box cdr-sb phase
risk higher dose dose
tau hypothesi still need
lack meaning clinic data
multipl failur anti-tau
need fund
fail advanc earli pipelin
program clinic studi
compani report medacorp physician interview leerink estim
dual platform
treatment paradigm alzheim diseas
current treatment paradigm alzheim diseas
ac immun opportun strategi
compani present
current treatment ad focu
symptom control late
genet imag diagnost
tool provid potenti earli
prevent on-tim disease-
modif sever
ac immun develop dual
technolog platform deliv
antibodi small molecul
solut ad treatment
portfolio product candid
target four differ type
rang indic
see synergist effect
compani effort toward
therapeut product
ac immun approach target misfold protein three differ pathway
misfold protein amyloid-beta tau shown play critic role ad well neurodegen
ac immun develop candid target multipl intervent point protein misfold patholog pathway
compani present
ac immun dual technolog platform morphom supraantigen
morphom differ target
antibodi vaccin robust antibodi respons
conformation-specif small molecul
larg librari small molecul
compani present
ac immun develop divers pipelin ad multipl partnership
crenezumab
crenezumab anti-abeta antibodi ad
what
crenezumab differenti bind affin abeta improv safeti profil enabl
longer treatment window higher dosag result potenti better cognit benefit
prodrom mild ad treatment
crenezumab deriv monoclon antibodi affin form abeta select
bind oligomer form therefor gener lower neuron-inflammatori respons
abbi high dose arm chang adas-cog
abbi high dose arm chang dsst
signific cognit effect observ non-
combin favor safeti profil
licens roche/genentech phase complet mix result two phase trial cread
on-going expect data read out respect fast-track design
patent portfolio three issu us patent three pend us patent expect expir
compani report public
form abeta
observ ad
observ abeta
senil plaqu ad
misfold aggreg plaqu accumul amyloid-beta wide observ ad patient
multipl high-profil antibodi target differ epitop abeta develop studi late-stag
crenezumab posit phase data help valid amyloid
view vivo pre-clin evid app transgen mice point
select bind oligomer abeta lack bind vascular amyloid
crenezumab select bind oligomer form abeta
crenezumab bind vascular amyloid
local crenezumab
absenc dens core affin
increas concentr
crenezumab control inject
transgen mice abeta bind data analyz day
absenc bind lead
lower risk neuroninflamm
vivo data collect mice model support rational increas efficaci lower side effect
crenezumab posit phase data help valid amyloid
view crenezumab differenti backbon compar
crenezumab backbon compar antibodi backbon
strong bind
aria- interim analysi
crenezumab distinct bind profil appear result lower aria- side effect differenti
aria- amyloid-rel imag abnorm edema
abeta program
crenezumab posit phase data help valid amyloid
view crenezumab differenti mechan support two phase
cognit efficaci phase
posit trend cognit
provid lower aria-
observ mild stage ad
bind multipl form
abbi cognit studi
reduct cognit declin
observ milder ad mmse
higher-dos arm
fibril
toxic form lower
abeta aggreg
function microglia
bind vascular amyloid offer
phase clinic data show
one case aria-
blaze biomark studi
consist reduct abeta
accumul observ
high dose arm measur
pet imag data
potenti higher dosag
phase data statist signific partial due small sampl size
posit trend toward cognit benefit milder ad subgroup well favor safeti data
support clinic develop despit mix phase readout
crenezumab posit phase data help valid amyloid
view proof-of-concept data collect two phase clinic trial
abbi blaze mild-to-moder ad patient
patient mild-to-moder ad mmse
enrol abbi studi
patient random take crenezumab
low dose sc high dose
primari endpoint week adas-
cogs cdr-sb global assess
secondari endpoint mmse dsst
patient florbetapir-
pet amyloid posit enrol
patient random take
crenezumab low dose
sc high dose iv
primari endpoint week
chang amyloid load baselin
measur pet imag
secondari endpoint csf mri
adas-cog cdr-sum box
crenezumab posit phase data help valid amyloid
view stat sig benefit observ abbi studi higher dose
arm non-predefin subgroup milder ad patient mmse
abbi high dose arm chang adas-cog
mild moder
abbi high dose arm chang dsst
mild moder
clear trend cognit effect observ toward milder ad patient indic import time ad treatment
crenezumab posit phase data help valid amyloid
view improv safeti profil observ blaze studi measur
pet imag biomark endpoint
blaze high dose arm chang amyloid load florbetapir-pet
chang total amyloid
deposit brain
blaze high dose arm chang adas-cog
mild moder
primari endpoint statist
signific clinic benefit amyloid
reduct observ
statist signific increas csf
observ indic
amyloid-beta elimin brain
exploratori analys two
score curv high-dos arm
blaze studi similar consist
abbi result
higher cognit respons observ
subgroup milder ad patient
although signific
trend confirm global
function cdr-sum box
consist trend cognit effect toward milder ad patient confirm blaze studi line abbi result
crenezumab posit phase data help valid amyloid
view crenezumab display larg effect size cognit
milder subgroup despit miss primari endpoint abbi blaze studi
ascs-adl adult social survey- activ daili live
differ calcul subtract pbo respons treatment
-- valu provid post-hoc analysi milder subgroup
crenezumab posit phase data help valid amyloid
view dose-depend respons support higher dosag treatment
phase clinic trial potenti higher efficaci
cdr-sb reduct higher dose arm phase
cognit effect favor treatment arm
cdr-sb
crenezumab test phase dosag simul result use cdr-sb primari endpoint
subdomain cdr-sb measur
crenezumab posit phase data help valid amyloid
view crenezumab also develop prevent ad
phase studi colombian patient secur support data
patient prodrom mild ad
primari endpoint chang cdr-sb week
studi
treatment time prodrom mild ad patient abeta
posit enrol ensur earli enough
bind affin flexibl bind profil strengthen
high dosag low edema risk
cognit function measur cdr-sb
week util primari endpoint phase studi
cread start data expect
cread start data expect
crenezumab select test first ever
ad prevent studi pre-symptom sponsor
cognit healthi member colombian famili
carri mutat toward earli ad onset risk
long-term prevent studi could provid data
evid support abeta hypothesi
enrol complet interim analysi
plan appear cancel final
readout expect
anti-abeta activ vaccin treatment diseas relat misfold amyloid-
beta ad syndrom ds
what
activ vaccin produc robust antibodi respons provid potenti long-term efficaci
liposom mimic amyloid-beta inject antigen stimul antibodi respons
oligomer fibrillari abeta protein abeta reduct cognition/memori effect
preclin data ad
nude mice
wt mice
preclin data ds
reduct abeta brain
pb nude mice
specif oligo/fibril
reduct abeta
level brain
enhanc
ad phase complet phase initi august
ds phase enrol complet interim data analysi expect
patent portfolio expect expir exclud hatch-waxman patent term extens
compani report public pihlgren et al blood muh et al pna belinchenko et al plo one
develop activ anti-abeta vaccin ad
activ immunotherapi misfold abeta protein
misfold abeta protein recogn human immun system
anti-abeta vaccin activ immunotherapi act abeta mimic
stimul immunotherapeut respons
subcutan inject enabl direct target abeta minim
ad vaccin program proof-of-concept studi includ
lundbeck/otsuka unit neurosci grifol
develop activ immunotherapi character safeti issu mix efficaci
activ vaccin ad consist synthet full-length peptid adjuv
phase studi termin due vaccine-induc brain inflamm enceph
beta-amyloid plaqu lower placebo minim cognit effect
indic import time
consist conjug multipl short fragment avoid lower brain
multipl phase clinic studi conduct termin without
combin multipl copi peptid fragment carrier particl
brain amyloid reduct observ app-transgen mice without cell activ
test multipl studi mix result
phase develop activ vaccin ad ds
phase studi ad
phase compet europ phase recruit
start august
patient treat year follow one
year shorten year due favor safeti
antibodi respons observ higher dose group
respons placebo
dose-depend efficaci observ measur
pet-imag cdr-sb
phase studi ds
syndrom carri extra copi chromosom
gene app regul
ad-rel neuropatholog amyloid posit
report ds patient age
age
clinical-stag vaccin target
abeta cognit patholog syndrom
phase studi recruit complet interim
analysi plan
preliminari phase data show favor safeti potenti efficaci proof-of-concept poc data need confirm result
hypothesi promis drug target ad diseas treatment
amyloid
target best
theori ad
one physician note door almost close amyloid hypothesi
anoth physician note pessim amyloid hypothesi cite amyloid may
correl cognit
physician indic amyloid may play import role ad probabl enough
explain condit
one physician believ amyloid tangl necessari ad
physician still believ amyloid patholog highli correl ad
physician still optimist anti-abeta cite import earli time vari
bind affin differ amyloid form
physician note on-going late-stag program aducanumab gantenerumab
crenezumab enough keep amyloid thesi hope aliv
physician like posit data aducanumab despit argument apo
group vasogen edema risk
crenezumab backbon lower safeti concern enabl higher dose
one physician note data question
anoth physician note small reaction somewhat excit doesnt
current data bacei point worsen cognit safeti issu physician
think still worth tri elenbecestat could differenti given higher select
medacorp physician interview
ac immun help valid tau patholog hypothesi anti-tau
view tau patholog promis target earli treatment ad
neurodegen diseas
tau accumul patholog occur later stage ad rel abeta
tau patholog close correl ad dementia abeta
misfold tau pursu next-gener ad biomark therapeut drug target
ac immun help valid tau patholog hypothesi anti-tau
view like ac immun rational approach target tau
patholog multipl intervent point
tau patholog spread lead neurofibrillari degener death neuron tau burden
appear directli correl cognit patholog
ac immun built product portfolio target tau intracellularli aggreg seed
extracellularli spread biolog small molecul
tau-pet imag agent develop in-hous collabor util companion diagnost
tool tau biomark
ac immun help valid tau patholog hypothesi anti-tau
view ac immun well-posit anti-tau therapeut
develop landscap three distinct program
phase
tangl solubl ptau
multipl high-profil tau program develop target differ form tau protein well
current avail clinic evid point potenti cognit benefit tau therapeut despit absenc
proof-of-concept data
therapeut activ anti-tau vaccin ad
what
robust antibodi respons potenti long-term effect
liposom mimic patholog tau protein aggreg ptau inject antigen
stimul antibodi respons tau patholog inhibit cognition/memori effect
immun respons specif ptau
gener robust antibodi respons select misfold phosphoryl tau
also gener favor safeti profil via t-cell activ independ mechan action
licens
phase complet phase readi new formul
patent portfolio expect expir exclud hatch waxman patent term extens
compani report press releas
ac immun help valid tau patholog hypothesi anti-tau
view develop activ vaccin anti-tau program base
phase studi ad
phase studi ad
patient mild moder
follow
synthet phosphoryl tau peptid
activ antigen stimul immuno-respons
four palmitoyl acid chain serv anchor
secur stabil conform
monophospholipid mpla ad
enhanc strengthen immunogen
candid phosphoryl patholog tau
phase treatment finish on-going
respect safeti toler data
observ phase studi t-cell induc
depend target specif antibodi respons
misfold phosphoryl tau
new formul anti-tau vaccin base
data develop aciu/j
advanc next phase
anti-tau antibodi passiv vaccin program gener highli specif inhibit
patholog form tau reduc effector function ad
what
antibodi gener highli specif inhibit patholog form tau reduc effector
function could potenti provid immedi long-term benefit
human monoclon antibodi bind extracellular isoform tau
protein inhibit cell-to-cel spread patholog tau
preclin evid reduct tau
clear reduct tau patholog observ mice
tau-reduct dose-depend effector-independ
concentr increas dose
well-toler healthi human
licens roche/genentech phase complet phase initi
ac immun help valid tau patholog hypothesi anti-tau
view preclin evid anti-tau antibodi show dose-depend
efficaci reduc effector function
neuron protect toxic tau presenc microglia absenc effector function
 oligo-p-tau anti-tau antibodi effector
dose-depend anti-tau immun tau-inhibit observ vivo full effector
effectorless environ target engag proven via dose-depend rise plasma tau
neuron protect toxic tau presenc microglia upon absenc effector
anti-tau antibodi reduc effector function minim microglia engag inflammatori
ac immun help valid tau patholog hypothesi anti-tau
view move phase studi support encourag
safeti pharmacolog data phase
patient
dose
follow
secondari endpoint pk data
favor safeti profil observ phase
dose-toler high dosag
dose-depend concentr detect
serum csf show exposur
data median half-lif day
observ ad patient compar healthi
compani file present
roch
use tau pet
phase data
support multipl
biomark attract tremend effort interest
physician like
ad diseas
misfold tau promis ad biomark therapeut target pend proof-of-concept data
play distinct role interact ab tau may exacerb tau patholog
seem increas focu metabol well inflammation-bas idea earli
interest approach
pkc show hint benefit interest worth look
diagnos ad
year
biomark seem predict amyloid hippocamp volum
pet approv diagnost workup symptom progress cognit impair
ad biomark test move research real practic physician diagnos patient
ad dont symptom
earli diagnosi critic ad treatment sinc amyloid plaqu build year
watch emerg csf biomark neurogranin add
strong
risk factor
link sever abeta independ pathogen pathway impair neuron signal
synapt function age-depend manner
allel lead high risk ad protect absenc
introduc high risk lower risk ad
target therapi need genotyp specif given isoform specif effect
drive amyloid patholog seed phase promot initi seed
growth phase support earli intervent
medacorp physician interview
program
ac immun advanc clinic pipelin product
view ac immun demonstr platform
multipl earli stage candid therapeut diagnost
compani file present
ac immun advanc clinic pipelin product
view ac immun develop broad strong collabor leverag
oper
compani present
disclosur limit due confidenti agreement
